超米兰标准原发性肝癌TACE治疗的研究进展

doi:10.11904/j.issn.1002-3070.2015.03.020

Abstract

Abstract:

Primary liver cancer(PLC)is one of the most invasive malignant tumors in the clinics.The PLC within Milan criteria can be cured by liver transplantation or liver resection.However,PLC exceeding Milan criteria has been a question for us to overcome all the time.In recent years,transcatheter arterial chemoembolization(TACE)and its combination therapy for PLC exceeding Milan criteria have made some breakthrough.A great deal of literatures have confirmed that TACE and its combined therapy for PLC exceeding Milan criteria can improve the survival rate obviously,it also contains many advantages,such as low cost,safe,painless,minimally invasive,repetitive operation and so on.The progress of TACE for PLC exceeding Milan criteria in recent years is summarized in this paper.

Key words: Exceeding milan criteria, Primary liver cancer, TACE

CLC Number:

R735.7

LIU Jia,LIU Ruibao. Progress on TACE treatment for primary liver cancer exceeding Milan criteria[J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(3): 279-283.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2015.03.020

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2015/V29/I3/279

References

1 Fortune BE,Umman V,Gilliland T,et al.Liver transplantation for hepatocellular carcinoma:a surgical perspective[J].J Clin Gastroenterol,2013,47(3):37-42.
2 Clavien P,Lesurtel M,Bossuyt PM,et al.Recommendations for liver transplantation for hepatocellular carcinoma:an international consensus conference report[J].Lancet Oncol,2012,13(2):11-22.
3 吴金平,吴辉,焦旭东,等.154例中晚期原发性肝癌介入治疗的回顾性分析[J].实用肿瘤学杂志,2012,22(4):339-341.
4 Benson AB,Abrams TA,Ben-Josef E,et al.NCCN clinical practice guidelines in oncology:hepatobiliary cancers[J].J Natl Compr Canc Netw,2009,7(4):350-391.
5 Arii S,Sata M,Sakamoto M,et al.Management of hepatocellular carcinoma:report of consensus meeting in the 45th annual meeting of the Japan society of hepatology[J].Hepatol Res,2010,40(7):667-685.
6 李倩,于友涛,王晓伟.部分脾栓塞术在原发性肝癌治疗中的应用研究[J].实用肿瘤学杂志,2014,28(3):285-288.
7 Herber S,Schneider J,Brecher B,et al.TACE:therapy of the HCC before liver transplantation-experiences[J].Fortschr Rintgenstr,2005,177(5):681-690.
8 Feng K,Yan J,Li X,et al.A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma[J].Journal of Hepatology,2012,57(4):794-802.
9 Wong KM,Yeh ML,Chuang SC,et al.Survival comparison between surgical resection and percutaneous radiofrequency ablation for patients in barcelona clinic liver cancer early stage hepatocellular carcinoma[J].Indian J Gastroenterol,2013,32(4):253-257.
10 Peng ZW,Lin XJ,Zhang YJ,et al.Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller:a retrospective comparative study[J].Radiology,2012,262(3):1022-1033.
11 Wang JH,Wang CC,Hung CH,et al.Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early stage hepatocellular carcinoma[J].J Hepatol,2012,56(2):412-418.
12 Peng ZW,Zhang YJ,Chen MS,et al.Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma:a prospective randomized trial[J].J Clin Oncol,2013,31(4):426-432.
13 Lu Z,Wen F,Guo Q,et al.Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma:A meta-analysis of randomized controlled trials[J].Eur J Gastroenterol Hepatol,2013,25(2):187-194.
14 Kim JH,Won HJ,Shin YM,et al.Medium-sized hepatocellular carcinoma:transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone[J].Ann Surg Oncol,2011,18(6):1624-1629.
15 Ni JY,Liu SS,Xu LF,et al.Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma:a meta-analysis[J].Journal of Cancer Research and Clinical Oncology,2013,139(4):653-659.
16 Xie LM.RFA combined with TACE for primary hepatic arcinoma[J].China Health Standard Management,2014,5(21):62-64.
17 Fang ZX,Song L,Xie HF,et al.Assessment of combining RFA with TACE for primary pepatic carcinoma[J].Jounal of Clinical Internal Medicine,2012,29(4):266-268.
18 张文兵,王宗华,谢鸿寿,等.CT引导下冷循环射频消融联合肝动脉热化疗栓塞治疗中晚期原发性肝癌[J].微创医学,2010,5(3):202-204.
19 朱一宁.肝动脉栓塞化疗联合经皮射频消融治疗肝癌[J].肝胆胰外科杂志,2005,17(02):120-122.
20 Yang P,Liang MH,Zhang YX,et al.Clinical application of a combination therapy of lentinan,multi-electrode RFA and TACE in HCC[J].Adv Ther,2008,25(8):787-794.
21 Cheng AL,Kang YK,Chen ZD,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase III randomised,double-blind,placebo-controlled trial[J].Lancet Oncol,2009,10(1):25-34.
22 Yang M,Yuan JQ,Bai M.Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma:a systematic review and meta analysis[J].Molecular Biology Reports,2014,41(10):6575-6582.
23 Liu H,Tao X,Ma F,et al.Radiosensitizing effects of arsenic trioxide on MCF-7 human breast cancer cells exposed to 89 strontium chloride[J].Oncol Rep,2012,28(5):1894-1902.
24 You BR,Park WH.Arsenic trioxide induces human pulmonary fibroblast cell death via increasing ROS levels and GSH depletion[J].Oncol Rep,2012,28(2):749-757.
25 Wen X,Li D,Zhang Y,et al.Arsenic trioxide induces cervical cancer apoptosis,but specifically targets human papillomavirus-infected cell populations[J].Anticancer Drugs,2012,23(3):280-287.
26 Wang T,Cui H,Ma N,et al.Nicotinamide-mediated inhibition of SIRT1 deacetylase is associated with the viability of cancer cells exposed to antitumor agents and apoptosis[J].Oncol Lett,2013,6(2):600-604.
27 贾树钊,杨树萌,杨艳梅,等.PTEN在三氧化二砷诱导肝癌细胞(SMMC-7721)凋亡中的作用[J].实用肿瘤学杂志,2012,26(4):302-304.
28 Alarifi S,Ali D,Alkahtani S,et al.Arsenic trioxide-mediated oxidative stress and genotoxicity in human hepatocellular carcinoma cells[J].Onco Targets Ther,2013,6(2):75-84.
29 颜廷华,徐卫东,谷文龙,等.三氧化二砷联合肝动脉化疗栓塞治疗中晚期原发性肝癌的临床观察[J].中国肿瘤临床与康复,2013,12(2):1377-1380.
30 Peng S,Yang QX,Zhang T,et al.Lobaplatin-TACE combined with radioactive ¹²⁵I seed implantation for treatment of primary hepatocellular carcinoma[J].Asian Pac J Cancer Prev,2014,15(13):5155-5160.
31 刘岩,刘瑞宝,王平,等.经导管植入¹²⁵I放射性粒子治疗肝癌伴门静脉癌栓19例[J].介入放射性杂志,2014,23(1):35-37.
32 Fang ZT,Yan ZP,Luo JJ,et al.Radomized comparative study of hepatocellular carcinoma with extensive portal vein tumor thrombus treated by TACE combined with or without endovascular implantation of iodine-125 seeds strand[J].Chinese Journal of Interventional Radiology,2013,1(1):8-13.
33 Luo JJ,Yan ZP,Wang JH,et al.Endovascular placement of iodine-125 seed strand and self-expandable stent combined with transcatheter arterial chemoembolization for hepatocellular carcinoma with tumor thrombus in the main portal vein[J].Zhonghua Zhongliu Zazhi,2011,33(7):535-539.
34 吴林霖,罗剑钧.门静脉支架及经动脉药物治疗栓塞联合或未联合血管内植入碘-125 粒子条治疗肝癌合并门静脉主干癌栓的比较[J].中华肝脏病杂志,2012,20(12):915-919.
35 Yang M,Fang Z,Yan Z,et al.Transarterial chemoembolisation(TACE)combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone:a two-arm,randomised clinical trial[J].J Cancer Res Clin Oncol,2014,140(4):687-688.
36 Duffy JP,Vardanian A,Benjamin EB,et al.Liver transplantation criteria for hepatocellular carcinoma should be expanded:A 22-year experience with 467 patients at UCLA[J].Ann Surg,2007,246(3):502-511.

[1]	DENG Jielian, ZHENG Wei, LI Kangjie, ZHANG Cong, ZHANG Yuan, XIE Biao, ZHONG Xiaoni. Construction of a prognostic risk prediction model in liver cancer for macrophage related genes based on single-cell RNA-seq and bulk RNA-seq data [J]. Journal of Practical Oncology, 2023, 37(5): 403-410.
[2]	SHI Linna, SUI Hong. Progress and challenges of immune checkpoint inhibitor therapy for primary hepatocellular carcinoma [J]. Journal of Practical Oncology, 2020, 34(6): 560-564.
[3]	ZHANG Lixia,PAN Shuanghua,HE Yingping. Study on the correlation between electrocardiogram and serum enzyme and electrolyte in patients with primary liver cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 523-526.
[4]	WANG Ye, CHANG Zhihui, ZHAO Xiangxuan, LIU Zhaoyu. The prognosis predicting effect of serum microRNA in the patients with hepatocellular carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 142-145.
[5]	YIN Linan, LIU Yan. Evaluation of microwave ablation treatment for liver cancer:a retrospective study of 187 cases [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(5): 395-399.
[6]	QIN Yanjuan,DING Ting. The recurrent risk factors of ethanol injection by interventional ultrasound on treatment of primary liver cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(3): 216-220.
[7]	KONG Jieyu,LI Shengmian. The efficacy evaluation of common antineoplastic drugs in TACE for primary hepatic carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(1): 82-85.
[8]	WANG Fa,WANG Honghui. Advance of transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2013, 27(5): 447-451.
[9]	LI Lupeng,ZHANG Jingyan,YU Youtao,HE Dongfeng. The expression of VEGF and P16 in hepatocellular carcinoma after TACE [J]. PRACTICAL ONCOLOGY JOURNAL, 2011, 25(3): 228-232.

Progress on TACE treatment for primary liver cancer exceeding Milan criteria

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 9

Recommended Articles

Metrics

Comments